BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mamula P, Markowitz JE, Cohen LJ, von Allmen D, Baldassano RN. Infliximab in pediatric ulcerative colitis: two-year follow-up. J Pediatr Gastroenterol Nutr. 2004;38:298-301. [PMID: 15076630 DOI: 10.1097/00005176-200403000-00013] [Cited by in Crossref: 66] [Cited by in F6Publishing: 52] [Article Influence: 3.9] [Reference Citation Analysis]
Number Citing Articles
1 Mahadevan U, Cucchiara S, Hyams JS, Steinwurz F, Nuti F, Travis SP, Sandborn WJ, Colombel JF. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn’s and Colitis Organisation: pregnancy and pediatrics. Am J Gastroenterol. 2011;106:214-223; quiz 224. [PMID: 21157441 DOI: 10.1038/ajg.2010.464] [Cited by in Crossref: 146] [Cited by in F6Publishing: 117] [Article Influence: 12.2] [Reference Citation Analysis]
2 Hyams JS, Lerer T, Griffiths A, Pfefferkorn M, Stephens M, Evans J, Otley A, Carvalho R, Mack D, Bousvaros A. Outcome following infliximab therapy in children with ulcerative colitis. Am J Gastroenterol. 2010;105:1430-1436. [PMID: 20104217 DOI: 10.1038/ajg.2009.759] [Cited by in Crossref: 88] [Cited by in F6Publishing: 68] [Article Influence: 7.3] [Reference Citation Analysis]
3 Olaiya B, Renelus BD, Filon M, Saha S. Trends in Morbidity and Mortality Following Colectomy Among Patients with Ulcerative Colitis in the Biologic Era (2002-2013): A Study Using the National Inpatient Sample. Dig Dis Sci 2021;66:2032-41. [PMID: 32676826 DOI: 10.1007/s10620-020-06474-1] [Reference Citation Analysis]
4 Gisbert JP, González-Lama Y, Maté J. Systematic review: Infliximab therapy in ulcerative colitis. Aliment Pharmacol Ther. 2007;25:19-37. [PMID: 17229218 DOI: 10.1111/j.1365-2036.2006.03131.x] [Cited by in Crossref: 93] [Cited by in F6Publishing: 79] [Article Influence: 6.2] [Reference Citation Analysis]
5 Haller CA, Markowitz J. IBD in children: lessons for adults. Curr Gastroenterol Rep 2007;9:528-32. [PMID: 18377807 DOI: 10.1007/s11894-007-0070-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
6 Eshuis EJ, Bemelman WA, Stokkers PC. Infliximab for the treatment of ulcerative colitis. Expert Review of Gastroenterology & Hepatology 2014;3:219-29. [DOI: 10.1586/egh.09.19] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
7 Magro F, Portela F. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies. BioDrugs. 2010;24 Suppl 1:3-14. [PMID: 21175228 DOI: 10.2165/11586290-000000000-00000] [Cited by in Crossref: 56] [Cited by in F6Publishing: 59] [Article Influence: 5.1] [Reference Citation Analysis]
8 Miehsler W, Novacek G, Wenzl H, Vogelsang H, Knoflach P, Kaser A, Dejaco C, Petritsch W, Kapitan M, Maier H. A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease. J Crohns Colitis. 2010;4:221-256. [PMID: 21122513 DOI: 10.1016/j.crohns.2009.12.001] [Cited by in Crossref: 60] [Cited by in F6Publishing: 55] [Article Influence: 5.0] [Reference Citation Analysis]
9 Dulai PS, Siegel CA, Dubinsky MC. Balancing and communicating the risks and benefits of biologics in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2013;19:2927-36. [PMID: 23867874 DOI: 10.1097/MIB.0b013e31829aad16] [Cited by in Crossref: 18] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
10 Romeo AC, Ventimiglia M, Dipasquale V, Orlando A, Citrano M, Pellegrino S, Accomando S, Cottone M, Romano C. Effectiveness and safety of biologics in pediatric inflammatory bowel disease: Real-life data from the Sicilian Network. Clinics and Research in Hepatology and Gastroenterology 2020;44:223-9. [DOI: 10.1016/j.clinre.2019.05.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
11 Lin YP, Thibodeaux CH, Peña JA, Ferry GD, Versalovic J. Probiotic Lactobacillus reuteri suppress proinflammatory cytokines via c-Jun. Inflamm Bowel Dis. 2008;14:1068-1083. [PMID: 18425802 DOI: 10.1002/ibd.20448] [Cited by in Crossref: 148] [Cited by in F6Publishing: 144] [Article Influence: 10.6] [Reference Citation Analysis]
12 McGinnis JK, Murray KF. Infliximab for ulcerative colitis in children and adolescents. J Clin Gastroenterol. 2008;42:875-879. [PMID: 18645529 DOI: 10.1097/mcg.0b013e3181354417] [Cited by in Crossref: 30] [Cited by in F6Publishing: 8] [Article Influence: 2.1] [Reference Citation Analysis]
13 Cottone M, Mocciaro F, Modesto I. Infliximab and ulcerative colitis. Expert Opinion on Biological Therapy 2006;6:401-8. [DOI: 10.1517/14712598.6.4.401] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
14 Cucchiara S, Morley-fletcher A. “New drugs: Kids come first”: Children should be included in trials of new biological treatments: . Inflammatory Bowel Diseases 2007;13:1165-9. [DOI: 10.1002/ibd.20045] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
15 Veres G, Baldassano RN, Mamula P. Infliximab Therapy in Children and Adolescents with Inflammatory Bowel Disease: . Drugs 2007;67:1703-23. [DOI: 10.2165/00003495-200767120-00005] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
16 Penagini F, Cococcioni L, Pozzi E, Dilillo D, Rendo G, Mantegazza C, Zuccotti GV. Biological therapy in pediatric age. Pharmacol Res 2020;161:105120. [PMID: 32783974 DOI: 10.1016/j.phrs.2020.105120] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
17 Nattiv R, Wojcicki JM, Garnett EA, Gupta N, Heyman MB. High-dose infliximab for treatment of pediatric ulcerative colitis: A survey of clinical practice. World J Gastroenterol 2012; 18(11): 1229-1234 [PMID: 22468086 DOI: 10.3748/wjg.v18.i11.1229] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
18 Tiemi J, Komati S, Sdepanian VL. Effectiveness of infliximab in Brazilian children and adolescents with Crohn disease and ulcerative colitis according to clinical manifestations, activity indices of inflammatory bowel disease, and corticosteroid use. J Pediatr Gastroenterol Nutr 2010;50:628-33. [PMID: 20386321 DOI: 10.1097/MPG.0b013e3181bbf481] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
19 Aloi M, Nuti F, Stronati L, Cucchiara S. Advances in the medical management of paediatric IBD. Nat Rev Gastroenterol Hepatol. 2014;11:99-108. [PMID: 23958601 DOI: 10.1038/nrgastro.2013.158] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
20 Stenke E, Hussey S. Ulcerative colitis: management in adults, children and young people (NICE Clinical Guideline CG166). Arch Dis Child Educ Pract Ed. 2014;99:194-197. [PMID: 24821990 DOI: 10.1136/archdischild-2013-305512] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
21 Rosen MJ, Minar P, Vinks AA. Review article: applying pharmacokinetics to optimise dosing of anti-TNF biologics in acute severe ulcerative colitis. Aliment Pharmacol Ther. 2015;41:1094-1103. [PMID: 25809869 DOI: 10.1111/apt.13175] [Cited by in Crossref: 63] [Cited by in F6Publishing: 47] [Article Influence: 9.0] [Reference Citation Analysis]
22 Moss AC, Peppercorn MA. Steroid-refractory severe ulcerative colitis: what are the available treatment options? Drugs. 2008;68:1157-1167. [PMID: 18547130 DOI: 10.2165/00003495-200868090-00001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
23 Watson S, Pensabene L, Mitchell P, Bousvaros A. Outcomes and adverse events in children and young adults undergoing tacrolimus therapy for steroid-refractory colitis. Inflamm Bowel Dis. 2011;17:22-29. [PMID: 20722055 DOI: 10.1002/ibd.21418] [Cited by in Crossref: 44] [Cited by in F6Publishing: 32] [Article Influence: 3.7] [Reference Citation Analysis]
24 Toussi SS, Pan N, Walters HM, Walsh TJ. Infections in children and adolescents with juvenile idiopathic arthritis and inflammatory bowel disease treated with tumor necrosis factor-α inhibitors: systematic review of the literature. Clin Infect Dis 2013;57:1318-30. [PMID: 23899685 DOI: 10.1093/cid/cit489] [Cited by in Crossref: 63] [Cited by in F6Publishing: 49] [Article Influence: 7.0] [Reference Citation Analysis]
25 Esposito S, Antoniol G, Labate M, Passadore L, Alvisi P, Daccò V, Ghizzi C, Colombo C, Principi N. Vaccines in Children with Inflammatory Bowel Disease: Brief Review. Vaccines (Basel) 2021;9:487. [PMID: 34064576 DOI: 10.3390/vaccines9050487] [Reference Citation Analysis]
26 Dulai PS, Thompson KD, Blunt HB, Dubinsky MC, Siegel CA. Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review. Clin Gastroenterol Hepatol. 2014;12:1443-1451; quiz e88-9. [PMID: 24462626 DOI: 10.1016/j.cgh.2014.01.021] [Cited by in Crossref: 94] [Cited by in F6Publishing: 79] [Article Influence: 11.8] [Reference Citation Analysis]
27 Grossman AB, Baldassano RN. Inflammatory Bowel Disease. Nelson Textbook of Pediatrics. Elsevier; 2011. pp. 1294-1304.e1. [DOI: 10.1016/b978-1-4377-0755-7.00328-6] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
28 Kelsen JR, Grossman AB, Pauly-Hubbard H, Gupta K, Baldassano RN, Mamula P. Infliximab therapy in pediatric patients 7 years of age and younger. J Pediatr Gastroenterol Nutr. 2014;59:758-762. [PMID: 25419596 DOI: 10.1097/mpg.0000000000000533] [Cited by in Crossref: 36] [Cited by in F6Publishing: 11] [Article Influence: 5.1] [Reference Citation Analysis]
29 Ruuska T, Wewer V, Lindgren F, Malmborg P, Lindquist M, Marthinsen L, Browaldh L, Casswall T, Kalliomäki M, Grönlund J. Granulocyte-monocyte adsorptive apheresis in pediatric inflammatory bowel disease: results, practical issues, safety, and future perspectives. Inflamm Bowel Dis. 2009;15:1049-1054. [PMID: 19137602 DOI: 10.1002/ibd.20859] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
30 Kugathasan S, Dubinsky MC, Keljo D, Moyer MS, Rufo PA, Wyllie R, Zachos M, Hyams J. Severe Colitis in Children: . Journal of Pediatric Gastroenterology and Nutrition 2005;41:375-85. [DOI: 10.1097/01.mpg.0000186272.65559.ce] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
31 de Ridder L, Benninga MA, Taminiau JA, Hommes DW, van Deventer SJ. Infliximab use in children and adolescents with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007;45:3-14. [PMID: 17592358 DOI: 10.1097/MPG.0b013e31803e171c] [Cited by in Crossref: 28] [Cited by in F6Publishing: 3] [Article Influence: 1.9] [Reference Citation Analysis]
32 Greifer MK, Markowitz JF. Update in the treatment of paediatric ulcerative colitis. Expert Opin Pharmacother 2006;7:1907-18. [PMID: 17020417 DOI: 10.1517/14656566.7.14.1907] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
33 Ziring DA, Wu SS, Mow WS, Martín MG, Mehra M, Ament ME. Oral tacrolimus for steroid-dependent and steroid-resistant ulcerative colitis in children. J Pediatr Gastroenterol Nutr. 2007;45:306-311. [PMID: 17873742 DOI: 10.1097/mpg.0b013e31805b82e4] [Cited by in Crossref: 45] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
34 Veereman-wauters G, de Ridder L, Veres G, Kolacek S, Fell J, Malmborg P, Koletzko S, Dias JA, Misak Z, Rahier J, Escher JC. Risk of Infection and Prevention in Pediatric Patients With IBD: ESPGHAN IBD Porto Group Commentary. Journal of Pediatric Gastroenterology & Nutrition 2012;54:830-7. [DOI: 10.1097/mpg.0b013e31824d1438] [Cited by in Crossref: 45] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
35 Grossman AB, Baldassano RN. Specific considerations in the treatment of pediatric inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2008;2:105-124. [PMID: 19072374 DOI: 10.1586/17474124.2.1.105] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
36 Sands BE, Kaplan GG. The role of TNFalpha in ulcerative colitis. J Clin Pharmacol. 2007;47:930-941. [PMID: 17567930 DOI: 10.1177/0091270007301623] [Cited by in Crossref: 84] [Cited by in F6Publishing: 89] [Article Influence: 5.6] [Reference Citation Analysis]
37 Puthoor PR, de Zoeten EF. Pediatric Ulcerative Colitis: The Therapeutic Road to Infliximab. Biol Ther. 2013;3:1-14. [PMID: 24392300 DOI: 10.1007/s13554-012-0006-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
38 Bradley GM, Oliva-Hemker M. Pediatric ulcerative colitis: current treatment approaches including role of infliximab. Biologics 2012;6:125-34. [PMID: 22740771 DOI: 10.2147/BTT.S31833] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
39 Biancone L, Michetti P, Travis S, Escher JC, Moser G, Forbes A, Hoffmann JC, Dignass A, Gionchetti P, Jantschek G, Kiesslich R, Kolacek S, Mitchell R, Panes J, Soderholm J, Vucelic B, Stange E. European evidence-based Consensus on the management of ulcerative colitis: Special situations. Journal of Crohn's and Colitis 2008;2:63-92. [DOI: 10.1016/j.crohns.2007.12.001] [Cited by in Crossref: 168] [Cited by in F6Publishing: 127] [Article Influence: 12.0] [Reference Citation Analysis]
40 de Bie CI, Escher JC, de Ridder L. Antitumor necrosis factor treatment for pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:985-1002. [PMID: 21936033 DOI: 10.1002/ibd.21871] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
41 Fanjiang G, Russell GH, Katz AJ. Short- and Long-term Response to and Weaning from Infliximab Therapy in Pediatric Ulcerative Colitis. Journal of Pediatric Gastroenterology & Nutrition 2007;44:312-7. [DOI: 10.1097/mpg.0b013e31802e98d4] [Cited by in Crossref: 44] [Cited by in F6Publishing: 15] [Article Influence: 2.9] [Reference Citation Analysis]
42 Carvalho R, Hyams JS. Diagnosis and management of inflammatory bowel disease in children. Semin Pediatr Surg 2007;16:164-71. [PMID: 17602971 DOI: 10.1053/j.sempedsurg.2007.04.003] [Cited by in Crossref: 29] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
43 Wong M, Ziring D, Korin Y, Desai S, Kim S, Lin J, Gjertson D, Braun J, Reed E, Singh RR. TNFalpha blockade in human diseases: mechanisms and future directions. Clin Immunol. 2008;126:121-136. [PMID: 17916444 DOI: 10.1016/j.clim.2007.08.013] [Cited by in Crossref: 182] [Cited by in F6Publishing: 182] [Article Influence: 12.1] [Reference Citation Analysis]
44 Akobeng AK. Infliximab for induction and maintenance theraphy for Ulcerative Colitis: . Journal of Pediatric Gastroenterology and Nutrition 2006;42:589-90. [DOI: 10.1097/01.mpg.0000221896.45910.9a] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
45 Wilson DC, Thomas AG, Croft NM, Newby E, Akobeng AK, Sawczenko A, Fell JM, Murphy MS, Beattie RM, Sandhu BK. Systematic review of the evidence base for the medical treatment of paediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2010;50 Suppl 1:S14-S34. [PMID: 20081542 DOI: 10.1097/mpg.0b013e3181c92caa] [Cited by in Crossref: 37] [Cited by in F6Publishing: 14] [Article Influence: 4.1] [Reference Citation Analysis]
46 Nobile S, Catassi C, Felici L. Herpes zoster infection followed by Henoch-Schönlein purpura in a girl receiving infliximab for ulcerative colitis. J Clin Rheumatol. 2009;15:101. [PMID: 19265360 DOI: 10.1097/rhu.0b013e31819bca9e] [Cited by in Crossref: 20] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
47 Bradley GM, Oliva-hemker M. Infliximab for the treatment of pediatric ulcerative colitis. Expert Review of Gastroenterology & Hepatology 2014;6:659-65. [DOI: 10.1586/egh.12.53] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
48 Doherty GA, Cheifetz AS. Management of acute severe ulcerative colitis. Expert Review of Gastroenterology & Hepatology 2014;3:395-405. [DOI: 10.1586/egh.09.24] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
49 Panaccione R, Fedorak RN, Aumais G, Bernard EJ, Bernstein CN, Bitton A, Croitoru K, Dieleman LA, Enns R, Feagan BG, Franchimont D, Greenberg GR, Griffiths AM, Marshall JK, Pare P, Patel S, Penner R, Render C, Seidman E, Steinhart AH. Review and clinical perspectives for the use of infliximab in ulcerative colitis. Can J Gastroenterol 2008;22:261-72. [PMID: 18354755 DOI: 10.1155/2008/493405] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
50 Targan SR, Karp LC. Defects in mucosal immunity leading to ulcerative colitis. Immunol Rev. 2005;206:296-305. [PMID: 16048556 DOI: 10.1111/j.0105-2896.2005.00286.x] [Cited by in Crossref: 116] [Cited by in F6Publishing: 110] [Article Influence: 6.8] [Reference Citation Analysis]
51 Vilar P, de Carpi JM, Acuña CE, Masiques ML. Infliximab in paediatric inflammatory bowel disease. Journal of Crohn's and Colitis 2007;1:2-9. [DOI: 10.1016/j.crohns.2007.07.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
52 de Zoeten E, Mamula P. What are the guidelines for using biologics in pediatric patients?: . Inflammatory Bowel Diseases 2008;14:S259-61. [DOI: 10.1097/00054725-200810001-00122] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]